Dr. Eric Kmiec, executive director and chief scientific officer of ChristianaCare’s Gene Editing Institute, has been selected as editor-in-chief of the scientific journal Gene and Genome Editing. Kmiec served three years on the journal’s board prior to this new position.
Kmiec is the founder and executive director of the ChristianaCare Gene Editing Institute. He is also the chief executive officer and scientific founder of CorriXR Therapeutics. He is widely recognized for his pioneering work in the fields of molecular medicine and gene editing. Throughout his career, Kmiec has led research teams in developing gene editing technologies and genetic therapies for inherited disorders and cancer.
His research has helped elucidate the regulatory circuitry that controls the gene editing of human cells. Current clinical research centers on developing CRISPR-based gene editing approaches for solid tumors. Squamous cell carcinoma of the lung and esophageal cancer are the lead protocols now advancing through the FDA approval process.
Gene and Genome Editing currently publishes methodological and translational research covering the spectrum of gene editing techniques and applications in any living organism. Its focus is on translational research with potential short- or long-term impact.
Click here to read the original press release.
